During a May earnings call, Medtronic executives expressed an appetite for M&A and pointed out it is a good time for deals.

Pressed for time? Here's the medtech news you need most, in one minute or less.

Dexcom CEO says the company has made progress on "several fronts" regarding the G7 pivotal trials, however the company is no longer disclosing timeline specifics.

This is the second-high profile collaboration San Diego, CA-based Tandem Diabetes Care has announced in recent weeks. Tandem also struck a deal that would call for its insulin delivery systems to be integrated into Abbott Laboratories’ Freestyle...

The two companies are in an agreement that would call for Tandem’s insulin delivery systems to be integrated with Abbott’s Freestyle Libre iCGM.

Pressed for time? Here's the medtech news you need most, in one minute or less.

The San Diego, CA-based company is acquiring Sugarmate, a developer of a mobile app for people with diabetes who use insulin. The deal is for an undisclosed sum.

San Diego, CA-based Dexcom’s solution allows for continuous glucose monitoring by measuring glucose levels automatically every five minutes and transmitting the data to a handheld mobile device, which can be accessed from a safe distance.

Abbott’s Freestyle Libre 2 iCGM can be used in adults and children over age 4 for a 14-day period. The Abbott Park, IL-based company also released promising data at the American Diabetes Association 80th Scientific Sessions this past weekend.